Advanced Treatments & Testing
SPRAVATO® Treatment in Chicago for Treatment-Resistant Depression
When depression has not improved enough with previous antidepressant treatment, it may be appropriate to consider another treatment approach.
Renovare Chicago evaluates eligible adults for SPRAVATO® (esketamine) treatment. SPRAVATO is an FDA-approved nasal spray for adults with treatment-resistant depression and may be used by itself or together with an oral antidepressant for that indication. (FDA Access Data) SPRAVATO® treatment takes place under healthcare-provider supervision and requires monitoring afterward. It is not a medication patients take home for unsupervised use. (FDA Access Data)
SPRAVATO® Treatment at a Glance
01
FDA-Approved for Adult TRD
SPRAVATO® is approved for adults with treatment-resistant depression.
02
Treatment happens in person
SPRAVATO® must be administered under direct healthcare-provider supervision.
03
At Least 2 Hours of Monitoring
Patients are monitored for at least two hours after each treatment.
Who it’s for
When to consider SPRAVATO®
SPRAVATO may be worth discussing when an adult continues to experience significant depression despite adequate antidepressant treatment.
In the FDA clinical program for treatment-resistant depression, patients had not responded adequately to at least two antidepressants of adequate dose and duration during the current depressive episode. (FDA Access Data)
Renovare may review your current symptoms, previous medications, treatment response, side effects, medical and psychiatric history, blood pressure, substance-use history, and other safety factors before determining whether SPRAVATO should be considered.
Not everyone with persistent depression is an appropriate candidate.
How Renovare Evaluates SPRAVATO® Eligibility
Treatment begins with a clinical evaluation rather than immediately scheduling a medication session.
Your provider reviews your depression history, previous antidepressant treatment, current medications, relevant medical conditions, and factors that could affect treatment safety.
SPRAVATO has specific contraindications and warnings, including concerns involving certain vascular conditions, previous intracerebral hemorrhage, blood-pressure increases, sedation, dissociation, respiratory depression, and abuse or misuse potential. (FDA Access Data)
Additional records or medical evaluation may be requested when needed.
How it works
Treatment options
Eligibility evaluation
We review your depression history, previous treatments, medical factors, and whether SPRAVATO® may be appropriate.
Supervised treatment sessions
You administer the prescribed nasal spray under direct healthcare-provider supervision.
Ongoing Response Monitoring
Your provider evaluates benefit, tolerability, and whether treatment frequency should continue or change.
GeneSight® and medication decisions
For selected patients, GeneSight pharmacogenomic testing may provide additional information about certain psychiatric medications.
GeneSight does not identify one guaranteed best medication and does not replace clinical evaluation.
Results are considered alongside your diagnosis, symptoms, medication history, side effects, medical conditions, and other clinical factors.
Medication management through telehealth
Many psychiatric medication follow-up appointments may be appropriate for secure telehealth.
Virtual visits may be used to review symptoms, side effects, treatment response, laboratory results, and medication plans.
Patients must be physically located in Illinois during a Renovare telehealth appointment.
An in-person visit may be recommended when physical assessment, reliable vital signs, testing, or medication-safety requirements make virtual care insufficient.
What to expect
What to expect
01
Complete Your Evaluation
We review your depression history, previous treatments, medications, and relevant health information.
02
Attend Supervised Treatment
If eligible, SPRAVATO is administered in the healthcare setting followed by required observation. (FDA Access Data)
03
Monitor Your Response
Your provider evaluates improvement, side effects, and whether continued treatment is appropriate.
Frequently Asked Questions
Who may qualify for SPRAVATO?
Eligible adults with treatment-resistant depression may be considered after an appropriate clinical evaluation.
Can SPRAVATO be taken at home?
No. It must be administered under healthcare-provider supervision in an appropriate certified healthcare setting.
How long will I remain after treatment?
Patients must be monitored for at least two hours and may need to remain longer depending on clinical status.
Can I drive after treatment?
Patients should not drive until the next day after restful sleep.
Is SPRAVATO the same as ketamine?
No. SPRAVATO contains esketamine and has FDA-approved psychiatric indications, while ketamine use for depression is off-label.
Does insurance cover SPRAVATO?
Coverage varies by health plan, and prior authorization may be required.
Insurance and Payment
Insurance plans may have specific medical-necessity and prior-authorization requirements for SPRAVATO. Renovare may need information about your diagnosis and previous antidepressant treatment as part of the authorization process. Insurance verification does not guarantee payment.
Request a SPRAVATO® evaluation
If depression has continued despite previous antidepressant treatment, Renovare can review your history and determine whether SPRAVATO or another treatment option may warrant further evaluation.
Submitting an appointment request does not establish a patient-provider relationship or guarantee a prescription, controlled medication, diagnosis, treatment, or insurance coverage.
Not an emergency service. For an immediate medical or psychiatric emergency, call 911 or go to the nearest emergency department.